OncoSec Medical (ONCS) Given Coverage Optimism Score of 0.12
Press coverage about OncoSec Medical (NASDAQ:ONCS) has trended somewhat positive recently, Accern reports. The research group identifies positive and negative news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. OncoSec Medical earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.7051470843362 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
OncoSec Medical (NASDAQ ONCS) opened at 0.95 on Friday. OncoSec Medical has a one year low of $0.88 and a one year high of $2.08. The firm’s market capitalization is $20.11 million. The stock has a 50 day moving average price of $1.02 and a 200-day moving average price of $1.15.
OncoSec Medical (NASDAQ:ONCS) last released its quarterly earnings data on Thursday, June 1st. The biotechnology company reported ($0.22) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.28) by $0.06. On average, equities analysts forecast that OncoSec Medical will post ($1.02) earnings per share for the current year.
A number of brokerages have commented on ONCS. ValuEngine upgraded OncoSec Medical from a “strong sell” rating to a “sell” rating in a research report on Friday, July 14th. Maxim Group set a $5.00 price objective on OncoSec Medical and gave the stock a “buy” rating in a research report on Saturday, June 3rd. Dawson James reiterated a “buy” rating and issued a $5.00 price objective on shares of OncoSec Medical in a research report on Thursday, July 6th. Noble Financial reiterated a “buy” rating on shares of OncoSec Medical in a research report on Wednesday, June 14th. Finally, HC Wainwright set a $6.00 price objective on OncoSec Medical and gave the stock a “buy” rating in a research report on Monday, June 12th. One analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $5.33.
ILLEGAL ACTIVITY WARNING: “OncoSec Medical (ONCS) Given Coverage Optimism Score of 0.12” was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://theolympiareport.com/2017/08/27/oncosec-medical-oncs-given-coverage-optimism-score-of-0-12.html.
OncoSec Medical Company Profile
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.
Receive News & Ratings for OncoSec Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.